TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from baseline in DAS28-CRP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Exogenous Carbohydrate Oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Glucose Turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with sustained partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sperm Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: recurrence rate of vaginal prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Symptom Checklist total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in albuminuria levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: bone mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: breast cancer incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Joint Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety of patients
Endpoint domain: Adverse events/effects
Primary endpoint: Serum levels of angiogenin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fitzpatrick Classification of Wrinkling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Degree of Elastosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mandibular Flexure in Occlusal Vertical Dimension (OVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mandibular Flexure in maximum opening (MO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T cell proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IVF outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CD4/CD25 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD33/CD11b/Lin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum immunoglobulins levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum levels of interferon gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: vascular complications in pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Interval cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 12-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary glycoaminoglycan (uGAG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Phantom and stump pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Neurocognitive effect based on MCCB score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Disease Activity Index (DAI) for Posterior Uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAI for Retinal vasculitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fludeoxyglucose (FDG) Uptake (SUVmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of contrast induced signal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Forced Expiratory Volume In 1 Second (FEV1) AUC0-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Morning serum cortisol (change from baseline measure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in the employment situation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in the housing situation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in the financial situation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in children's situation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: FEV1 response to bronchodilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of personalized treatment initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of molecularly stratified treatment options
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Expression of PD-L1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of MRI staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nominal Change From Baseline in Inflammatory Lesion (IL) Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough flow volume indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Gingival Health Measured by Bleeding Index (BI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Concentrations of RO7234292 in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Concentrations of RO7234292 in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mHTT (Mutant Huntingtin) Concentration in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of treatment responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Clinically Significant Vital Signs and Electrocardiogram (ECG) Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Serum Calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients who received ITEOL
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Asthma Control Test (ACT) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical remission at 6 or 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of a severe life threatening adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective measurements of comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Readmission to the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Cure at end of study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Incidence of moderate/severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epigenetic modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic floor muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PVR (Post-Void Residual)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Mean Subjective Mood Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mean Psychomotor Task Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lesion detection and quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall Reliability of Monitoring Technology
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Central Corneal Swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total liver volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to Local and Distant Progression
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of all-cause hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: breast cancer progression
Endpoint domain: Mortality/survival
Primary endpoint: Modified Rankin Scale Score (mRS) 0-2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number and percentage of participants with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum concentration of ABT-414
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total fecal bile acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total fecal short chain fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fecal microbial population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the plasma concentration - time curve from time of dosing to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peak Endpoint Reaching Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Reaching Work Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Change in Tumor Volume Using Mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median Change in Tumor Volume Using MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Grade and number of cytokine release syndrome and neurotoxic effects
Endpoint domain: Adverse events/effects
Primary endpoint: Persistence of anti-CD19 CAR-T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Assisting Hand Assessment (AHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with grade 2 or higher complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change of non-optimal timing adherence to DOACs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: device- or procedure related SAE rate
Endpoint domain: Adverse events/effects
Primary endpoint: PE, DVT and ischemic stroke and atrial fibrillation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Effective PFO closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity and specificity of RedScar© application to detect surgical infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Accepting mathematical model
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Difference in Westley croup score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Walking Index for Spinal Cord Injury (WISCI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 10 Meter Walk Test (10mWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major adverse cardiac or cerebrovascular events free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment outcome in psoriasis patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute change in step counts per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of areas under the curve of IGF-1 concentration from baseline (ΔIGF-1 AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in concentration of plasma-STAT3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of positive lymph nodes after neoadjuvant chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Evaluation of complications related to the surgical procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Median Effective Concentration (EC50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Umbilical Cord pH Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk factors for civilization diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of co-administration of nizatidine & metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic Energy Fluxes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose (MTD) of sorafenib tosylate
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of hepatic disease as assessed by the Child-Pugh criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of subjects with TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Burnout as measured by the Maslach Burnout Inventory Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 7-day point prevalence abstinence from smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maximal Postural Tachycardia During Tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean Change in Panic Disorder Severity Scale (PDSS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Fasting Serum Potassium Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change in Mammographic Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood-oxygen-level-dependent contrast (BOLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in aggression behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barratt Impulsiveness Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality of life of long-term survivors
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self and informant report of cognitive difficulties
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self report of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Quality of Life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MDS-UPDRS Motor III Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants With Increased Motor Cortex and Thalamus Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Body Image Scale (BIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Restoration Retention Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Plasma Concentration-time Curve Over the Dosing Interval of 24 Hours (AUC[TAU])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rest and dynamic postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rescue analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: appearance of bowel sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and tolerability of oral dosing with XL147
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of XL147
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in visual acuity (BCVA score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Intervention Measure (FIM)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participation Strategies Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PROMIS-Self-Efficacy Short Forms
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Patients With a Negative Sputum Culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and Tolerability of the 2 Intensive Phase Regimens
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in 24-hour Average Ambulatory Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma and Serum Testosterone Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sensory/hedonic rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in psycho-social and behavioural scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in motor skills scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ideal positioning rate of LMA flexible
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adjusted Mean Change in Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased M/M infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with hemodynamic reactivity, hypotension or bradycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: macrophage uptake of apoptotic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean number of items accurately classified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in baseline flow mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma glucagon area under curve values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Oro-nasal Fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate-specific antigen (PSA) free survival
Endpoint domain: Mortality/survival
Primary endpoint: interleukin-6 (IL-6) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor Growth Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Constant Work Rate Exercise Endurance Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Benefit Ratio (CBR)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: percentage of complete abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Verbal Learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound parameters of peripheral artery plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Daytime and nocturnal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analog scale (VAS) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes